Business Context and Reporting Period
Oragenics, Inc. (OGEN) filed a Form 8-K on December 15, 2021, reporting a material definitive agreement. The company is incorporated in Florida and trades on the NYSE American. The filing focuses on an amendment to a Technology License Agreement with the National Research Council of Canada (NRC).
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- License Amendment: On December 15, 2021, the Company amended its Technology License Agreement with the NRC (originally dated July 26, 2021).
- Scope Expansion: The amendment specifically includes the trimeric spike protein Omicron variant within the scope of the NRC License.
- Terms: All other terms of the License remained unchanged from the version filed as Exhibit 10.0 to the Company's Form 10-Q filed on November 15, 2021.
Guidance, Outlook, and Risks
The filing references a press release issued on December 20, 2021, announcing the extension of the License Agreement to add the Omicron variant. No specific financial guidance, management outlook, or discussion of risks and contingencies is provided within the text of this 8-K filing.
Investor Verification Checklist
- Verify the specific terms and royalty obligations associated with the Omicron variant addition in the amended NRC License.
- Review the original Technology License Agreement filed as Exhibit 10.0 to the November 15, 2021 Form 10-Q to understand the baseline terms.
- Confirm the status of the Company's interim leadership, as the report was signed by Michael Sullivan, Interim Principal Executive Officer and Chief Financial Officer.
- Check the attached press release (Exhibit 99.1) for additional details on the commercial implications of the Omicron variant inclusion.